An observational study in Coronary Artery Disease, Physical Activity and Lifestyle, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 3 sites in Belgium. Open to male participants aged 45 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-03.
Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Coronary Artery Disease by Universitaire Ziekenhuizen KU Leuven — 4 open to participants now, 4 under way, none of them phase 3. Coronary Artery Disease · Universitaire Ziekenhuizen KU Leuven.
Among the 10 studies in Coronary Artery Disease by Universitaire Ziekenhuizen KU Leuven, this one is the only one that started in 2018, is one of 4 observational ones, and was the 6th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →4 of the 10 studies in Coronary Artery Disease by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 45 Years to 70 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,800 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 62 across the 6 interventional studies, 133 across the 4 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 268 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Coronary Artery Disease by Universitaire Ziekenhuizen KU Leuven that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07036770Universitaire Ziekenhuizen KU LeuvenCoronary Evaluation And Guided Lesion Exploration Using Photon-counting CT and Intracoronary Imaging Techniques | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Coronary Artery Disease by Universitaire Ziekenhuizen KU Leuven, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the Master@Heart Trial is to investigate whether lifelong endurance exercise reduces the incidence of non-calcified plaques (both mixed and soft plaques) as compared to late-onset endurance exercise and a non-athletic lifestyle.
Cardiovascular disease remains the leading cause of death in Europe and is strongly related to a sedentary lifestyle combined with inadequate dietary habits and the prevalence of smoking. In parallel with this modern inactivity pandemic, the past 2 decades we have also witnessed an increase in the number of middle-aged and older individuals engaging in competitive sports and mass exercise events, such as marathon-running and cycling events. This increasing popularity of endurance sports implies that a greater proportion of individuals participating in high-intensity sport will have a higher cardiovascular risk profile. Coronary artery disease is by far the most common cause of sudden cardiac death in senior athletes, accounting for >75% of all cardiac deaths during exercise. Each case of sudden cardiac death is always a dramatic event and is often widely publicized in the media, thereby raising issues and questions regarding the safety of intense sports participation. Debate and uncertainty persist with much speculation filling the space left by an incomplete understanding of the exercise dose-response relationship. In view of the importance of exercise for healthy ageing, it is important to identify and eliminate any adverse associations with exercise so that everyone can enjoy the benefits of exercise. Until present, no studies have compared the 'standard of care,' which includes a healthy diet, abstinence from smoking, and regular moderate exercise, with and without the addition of larger doses of endurance exercise. Furthermore, it remains unknown whether the age of onset of endurance training influences its potential preventive and adverse effects.
Until present, no studies have compared the 'standard of care,' which includes a healthy diet, abstinence from smoking, and regular moderate exercise, with and without the addition of long-term endurance exercise. In this multicentre project we will investigate the beneficial effects of long-term endurance exercise for the prevention of coronary and carotid artery disease and its potential adverse effects, such as an increased incidence of atrial fibrillation and myocardial fibrosis. We will recruit 3 age-matched cross-sectional cohorts: (1) lifelong endurance athletes engaged in regular endurance sports practice since the age of 30 years, (2) late-onset endurance athletes who have initiated endurance sports activities after the age of 30 years and (3) non-athletic individuals. Only male subjects will be included given the much lower prevalence of ischemic heart disease amongst female athletes.
Cohort 1: Lifelong endurance athletes. Inclusions: Athletes who have initiated endurance sports activities at regional, national or international level before the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing.
Cohort 2: Late-onset endurance athletes. Athletes who have initiated endurance sports activities at regional, national or international level after the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing.
Cohort 3: Healthy non-athletes will be recruited from subjects seen in the outpatient clinic for a work-related medical check-up, from university alumni and from multisports organisations. Participation in regular sports with a low dynamic component (e.g. billiards, darts or bowling) >3 hours /week is allowed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Lifelong endurance athletes:
Involved in competition and high-level training:
Late-onset endurance athletes:
Involved in competition and high-level training:
Healthy non-athletes
Exclusion Criteria:
i) Athletes who have initiated endurance sports activities at regional, national or international level before the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (\> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.
i) Athletes who have initiated endurance sports activities at regional, national or international level after the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (\> 5 pack years) or diabetes, ii) they have a history of smoking (\> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.
Healthy non-athletes will be recruited from subjects seen in the outpatient clinic for a work-related medical check-up, from university alumni and from multisports organisations. Subjects will be excluded if they: i) had been involved in regular sports practice more than \>3 hours / week, ii) have a history of smoking (\> 5 pack years) or diabetes, or iii) had been diagnosed with a cardiopulmonary disorder prior to inclusion. Participation in regular sports with a low dynamic component (e.g. billiards, darts or bowling) \>3 hours /week is allowed.
Incidence of Non-calcified Plaques
Incidence of non-calcified plaques (both mixed and soft plaques) assessed by Coronary CT in lifelong endurance athletes as compared to late-onset endurance athletes and non-athletic subjects.
Time frame: 2 years
Incidence of Atrial Fibrillation
To assess the association between the (a) amount and (b) starting age of lifelong endurance sports and atrial fibrillation assessed by Holter monitoring
Time frame: 4 years
Prevalence of Myocardial Fibrosis
To assess the association between the (a) amount and (b) starting age of lifelong endurance sports and myocardial fibrosis assessed by cardiac magnetic resonance imaging
Time frame: 2 years
Arterial Stiffness
To assess arterial stiffness by Applanation Tonometry in lifelong endurance athletes versus late-onset athletes and non-athletic individuals.
Time frame: 2 years
Carotid Intima Thickness
To assess carotid intima thickness by Doppler Ultrasound in lifelong endurance athletes versus late-onset athletes and non-athletic individuals.
Time frame: 2 years
Left Ventricular Diastolic Function
To assess left ventricular diastolic function by echocardiography in lifelong endurance athletes versus late-onset athletes and non-athletic individuals.
Time frame: 2 years
Plan to share: Undecided
Ran from Oct 2018 to primary completion in Oct 2021, 35 months.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's 35 months is below that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitaire Ziekenhuizen KU Leuven →